world1 outlet covering this

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients

First publishedJun 30, 21:29 UTC

Last updatedJul 12, 12:32 UTC · 14m ago

↻

each logo = when that outlet publishedlast updated on Braven

Story signals

How strong is this topic?

High significance means broad impact or urgency. Source trust reflects the average authority of outlets covering the story.

Significance5.3

Weighted from impact, urgency, coverage breadth, and topic sensitivity.

Source trust10.0

Average reliability level of outlets included in this topic.

Outlets1

Independent sources contributing to this topic cluster.

More outlets usually means a more confirmed developing story.

The report

The U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Read the full report at FDA ↗

Related in the knowledge graph

organizationBlood Cancer Patients. The organizationCells organizationDrug Administration organizationFDA Approves New Treatment organizationGVHD organizationPrevent Serious Complications organizationTreg organizationTREGZI

Sources (1)

Avg source rating 10.0/10

FDA10